Last $63.52 USD
Change Today +0.04 / 0.06%
Volume 618.6K
DGX On Other Exchanges
Symbol
Exchange
New York
Stuttgart
As of 4:15 PM 11/20/14 All times are local (Market data is delayed by at least 15 minutes).

quest diagnostics inc (DGX) Snapshot

Open
$62.96
Previous Close
$63.48
Day High
$63.54
Day Low
$62.95
52 Week High
11/13/14 - $64.65
52 Week Low
02/7/14 - $50.46
Market Cap
9.2B
Average Volume 10 Days
1.6M
EPS TTM
$4.05
Shares Outstanding
144.5M
EX-Date
10/3/14
P/E TM
15.7x
Dividend
$1.32
Dividend Yield
2.03%
Current Stock Chart for QUEST DIAGNOSTICS INC (DGX)

quest diagnostics inc (DGX) Related Businessweek News

View More BusinessWeek News

quest diagnostics inc (DGX) Details

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. It offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices; and risk assessment services for the life insurance industry. The company also develops, manufactures, and markets diagnostic products, including Simplexa molecular chemistries for testing infectious disease and hospital-acquired infections; HerpeSelect HSV serology; and DxSelect IFA and ELISA products for testing infectious diseases. In addition, it provides molecular diagnostic products in various segments, such as HIV-1 drug resistance testing under the ViroSeq brand name; and reproductive genetics and transplantation under the brand names of Atria and AlleleSeqr. Further, the company offers Care360 EHR, a solution that allows doctors to electronically create, manage, and distribute patient encounter notes, including vital signs and progress notes; and ChartMaxx, an electronic document management system for hospitals. The company offers its diagnostic information services to patients, physicians, hospitals, integrated delivery networks, health plans, employers, and others through a network of laboratories, patient service centers, and phlebotomists in physician offices. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Madison, New Jersey.

41,000 Employees
Last Reported Date: 02/18/14
Founded in 1967

quest diagnostics inc (DGX) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $472.1K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $573.9K
Senior Vice President of Clinical Franchises
Total Annual Compensation: $520.0K
Senior Vice President and General Counsel
Total Annual Compensation: $492.1K
Compensation as of Fiscal Year 2013.

quest diagnostics inc (DGX) Key Developments

Quest Diagnostics Not To Acquire a CRO

Steve Rusckowski, Chief Executive Officer of Quest Diagnostics Inc. (NYSE:DGX) said his company will stick to its core business of diagnostic testing and is not interested in acquiring a contract research organization (CRO). Steve Rusckowski said in an interview that his company is not interested in straying very far from its focus on diagnostic information services. "What we don't have, and we believe is not in the scope of diagnostic information services is a clinical research organization," Steve Rusckowski said. "We believe the scope we have in diagnostic information services is broad enough and good enough for us to support our growth goals".

Quest Eyes Acquisitions

Quest Diagnostics Inc. (NYSE:DGX) is looking for acquisition opportunities. Quest expects to continue to achieve sequential improvement in organic revenue growth, with overall average revenue growth of 2% to 5% over the next three years. This expected revenue growth includes potential acquisitions.

Quest Diagnostics Introduces BRCAvantage Plus

Quest Diagnostics announced BRCAvantage Plus, the company's suite of lab-developed test services for assessing genetic breast cancer risk based on clinically validated non-BRCA as well as BRCA genes. The new service is now available in all 50 states. BRCAvantage Plus is the first major line extension to BRCAvantage, a suite of lab-developed tests for assessing BRCA1 and BRCA2 gene mutations launched in October 2013. BRCAvantage Plus screens for mutations (point mutations, deletions, and duplications) in the BRCA1 and BRCA2 genes as well as in five additional genes: TP53, PTEN, CDH1, STK11, and PALB2. While mutations in the BRCA1 and BRCA2 genes result in 15% to 20% of inherited breast cancers, recent research indicates that mutations in these five non-BRCA genes account for an additional 3% to 4.5% of inherited breast cancers. Individuals who test positive for a mutation may consider more intensive monitoring or medical or surgical intervention to decrease risk of death from cancer in conjunction with their physician and in consideration of medical evidence and guidelines. Other unique capabilities of BRCAvantage Plus include: Based on the advanced technologies and scientific knowledge. The BRCAvantage family of services is based on next-generation gene sequencing and multiplex ligation-dependent probe amplification, for analytical sensitivity and specificity of over 99.99% in the company's assay validation study. In addition, identified variants are cross referenced with mutational databases to promote reliable clinical interpretation. Quest is also participating in ongoing collaborative studies to further the understanding of specific mutations together with academic medical centers, including Memorial Sloan Kettering Cancer Center in New York. Access to expert genetic counselors to guide physicians and patients through the risk assessment process. A national survey by Quest Diagnostics and Harris Interactive found significant confusion among women polled about BRCA testing, with 82% claiming they would not know what to do with a positive BRCA gene test result if they received one. Quest Diagnostics encourages patients to consult a genetic counselor as well as their physician to understand the clinical need for and medical significance of all genetic cancer-risk tests. As part of the BRCAvantage service, Quest helps patients identify a non-Quest employed genetic counselor for consultation. Physicians may consult a Quest Diagnostics genetic counselor for assistance in test selection and interpretation. Pre-authorization support. Through its relationships with health plans across the United States, Quest Diagnostics helps patients identify if BRCAvantage testing is covered by their individual plan. National access to testing. After a physician orders a test, patients can submit blood specimens for testing at Quest's about 2,000 patient service centers located across the United States, for geographic convenience unmatched by any other BRCA test provider.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DGX:US $63.52 USD +0.04

DGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cepheid $52.06 USD -0.19
Covance Inc $100.87 USD +0.20
Hologic Inc $26.39 USD +0.10
Laboratory Corp of America Holdings $100.64 USD -0.31
QIAGEN NV €18.87 EUR -0.064
View Industry Companies
 

Industry Analysis

DGX

Industry Average

Valuation DGX Industry Range
Price/Earnings 18.4x
Price/Sales 1.3x
Price/Book 2.2x
Price/Cash Flow 15.4x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUEST DIAGNOSTICS INC, please visit www.questdiagnostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.